New drug combo shows promise for rare childhood leukemia

NCT ID NCT07437170

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a drug called selinexor to standard chemotherapy can help children with a specific, high-risk form of acute myeloid leukemia (NUP98-positive AML). Ten children will receive the combination during their first two rounds of treatment. The goal is to see if more children achieve complete remission and have no detectable cancer cells left.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Selinexor (a drug that blocks a protein helping cancer cells survive) combined with standard chemotherapy drugs (homoharringtonine, cytarabine, and G-CSF)

What this could lead to

If successful, this could offer a more effective treatment option for children with a hard-to-treat form of leukemia, potentially leading to higher remission rates and longer survival.

What could go wrong

This is a very small early-phase trial with only 10 participants, so results may not apply to all patients. Adding selinexor to chemotherapy may also increase side effects like nausea, fatigue, or low blood counts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia childhood acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China